Cargando…

Second-line antiretroviral therapy regimen change among adults living with HIV in Amhara region: a multi-centered retrospective follow-up study

OBJECTIVE: This study was conducted to determine the rate of initial second-line ART regimen change and its predictors among adults living with HIV in Amhara region. A retrospective follow-up study was conducted between February, 2008 and April, 2016 at eight governmental hospitals of Amhara region....

Descripción completa

Detalles Bibliográficos
Autores principales: Alene, Muluneh, Awoke, Tadesse, Yenit, Melaku Kindie, Tsegaye, Adino Tesfahun, Yismaw, Leltework, Yeshambel, Reta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6632209/
https://www.ncbi.nlm.nih.gov/pubmed/31307513
http://dx.doi.org/10.1186/s13104-019-4429-3
Descripción
Sumario:OBJECTIVE: This study was conducted to determine the rate of initial second-line ART regimen change and its predictors among adults living with HIV in Amhara region. A retrospective follow-up study was conducted between February, 2008 and April, 2016 at eight governmental hospitals of Amhara region. Person-times and Cox proportional hazard model were fitted to determine the rate and to identify the significant predictors of second-line treatment regimen change. RESULTS: A total of 897 records of patients were analyzed. The overall rate of initial second-line drug regimen change was 24.2 per 100 person years. The rate of regimen change was decreased for patients with formal education (HR: 0.77, 95% CI 0.61–0.97), under WHO clinical stage-III (HR: 0.57, 95% CI 0.45–0.73), and WHO clinical stage-IV (HR: 0.64, 95% CI 0.43–0.96). Patients who were taking CPT (HR: 2.05, 95% CI 1.45–2.89) had an increased rate of regimen change. Furthermore, the rate of regimen change was decreased for patients who were switched to second-line treatment due to virological failure (HR: 0.36, 95% CI 0.25–0.53), and due to drug toxicity (HR: 0.48, 95% CI 0.28–0.81). Therefore, addressing significant predictors to maximize the durability on the initial regimen among ART clients is essential. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13104-019-4429-3) contains supplementary material, which is available to authorized users.